Medac Gesellschaft für klinische Spezialpräparate m.b.H.

Medexus Pharmaceuticals may pay Medac GmbH $15M-$45M if FDA approves treosulfan, with payments spread over FY26. Leede Financial maintains a CA$8.25 target price, suggesting a 200% return potential. Medexus projects treosulfan could achieve $100M in peak U.S. sales within five years.

medac and chiron biotechnology collaborate to develop animal-free testing methods using organ-on-chip technology, focusing on methotrexate for rheumatoid arthritis.

UroGen Pharma announces Q3 2024 financial results, including $25.2M in JELMYTO net product sales. The FDA accepted the New Drug Application for UGN-102 with a PDUFA target action date of June 13, 2025. UroGen reported $254.2M in cash, cash equivalents, and marketable securities as of September 30, 2024. A conference call and webcast will be held on November 6, 2024, at 10:00 AM ET.

MP Nigdelis received honoraria from RG Ärztefortbildung GmbH and travel grants from Organon and Gedeon Richter. M Doerk received travel grants from Gedeon Richter, Organon, and Eisai, and is a member of DGGG, AGE, and Deutsche Gesellschaft für Senologie. S Burghaus received honoraria from FOMF and is a member of DGGG, AGEM, AGE, Stiftung Endometriose Forschung, AGUB, AGO, and DKK. M Sillem, CEO of EuroEndoCert Gmbh, received payments from Bayer, Gedeon Richter, Hologic, and EndoHealth. B Haj Hamoud received travel grants from Gedeon Richter, Astrazeneca, Johnson & Johnson, and Storz, and is a member of DGGG, AGE, and Stiftung Endometriose Forschung. EF Solomayer receives grants from the University of Saarland, Storz, and Erbe, and fees from Roche, Pfizer, Celgene, Amgen, Astra Zeneca, Esai, Johnson & Johnson, Novartis, Tesaro, Teva, Medac GmbH, MSD, Vifor, Gedeon Richter, Takeda, and AGE, among others. GL Olmes received grants from AstraZeneca, Universitätsklinikum Freiburg, and RG Ärztefortbildung GmbH, and is a member of DGGG, AGE, and AGEM, with scientific collaboration with Karl Stotz.